Evidence map›Paper›PMID 35892638›Full record

ArticleAntioxidants (Basel, Switzerland)2022

Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases.

Daniela Scarabino, Liana Veneziano, Alessia Fiore, Suran Nethisinghe, Elide Mantuano, Hector Garcia-Moreno, Gianmarco Bellucci, Nita Solanky, Maria Morello, Ginevra Zanni and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Daniela ScarabinoInstitute of Molecular Biology and Pathology, National Research Council, 00185 Rome, Italy.ORCID 0000-0002-5565-6379
Liana VenezianoInstitute of Translational Pharmacology, National Research Council, 00133 Rome, Italy.ORCID 0000-0002-9921-8450
Alessia FioreDepartment of Biology and Biotechnology, Sapienza University of Rome, 00185 Rome, Italy.
Suran NethisingheAtaxia Center, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, University College, London WC1N 3BG, UK.ORCID 0000-0002-4272-9292
Elide MantuanoInstitute of Translational Pharmacology, National Research Council, 00133 Rome, Italy.ORCID 0000-0003-1656-5543
Hector Garcia-MorenoAtaxia Center, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, University College, London WC1N 3BG, UK.ORCID 0000-0002-0697-3271
Gianmarco BellucciDepartment of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-2635-1699
Nita SolankyAtaxia Center, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, University College, London WC1N 3BG, UK.
Maria MorelloDepartment of Experimental Medicine and Surgery, Tor Vergata University, 00133 Rome, Italy.
Ginevra ZanniUnit of Neuromuscolar and Neurodegenerative Disorders, Department of Neurosciences, Bambino Gesù Children's Research Hospital, IRCCS, 00100 Rome, Italy.ORCID 0000-0002-6367-1843
Rosa Maria CorboDepartment of Biology and Biotechnology, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-1091-2498
Paola GiuntiAtaxia Center, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, University College, London WC1N 3BG, UK.
National Hospital for Neurology and Neurosurgery · GBSapienza University of Rome · ITIstituto di Farmacologia Traslazionale · ITBambino Gesù Children's Hospital · ITInstitute of Molecular Biology and Pathology · ITUniversity of Rome Tor Vergata · IT

Funding

Medical Research Council MR/N028767/1
6 · The paper itself

Abstract

SCA1, SCA2, and SCA3 are the most common forms of SCAs among the polyglutamine disorders, which include Huntington's Disease (HD). We investigated the relationship between leukocyte telomere length (LTL) and the phenotype of SCA1, SCA2, and SCA3, comparing them with HD. The results showed that LTL was significantly reduced in SCA1 and SCA3 patients, while LTL was significantly longer in SCA2 patients. A significant negative relationship between LTL and age was observed in SCA1 but not in SCA2 subjects. LTL of SCA3 patients depend on both patient's age and disease duration. The number of CAG repeats did not affect LTL in the three SCAs. Since LTL is considered an indirect marker of an inflammatory response and oxidative damage, our data suggest that in SCA1 inflammation is present already at an early stage of disease similar to in HD, while in SCA3 inflammation and impaired antioxidative processes are associated with disease progression. Interestingly, in SCA2, contrary to SCA1 and SCA3, the length of leukocyte telomeres does not reduce with age. We have observed that SCAs and HD show a differing behavior in LTL for each subtype, which could constitute relevant biomarkers if confirmed in larger cohorts and longitudinal studies.

Indexed as

biomarkersleukocyte telomere lengthneurodegenerative diseasesspinocerebellar ataxias

Identifiers

PMID35892638
PMCPMC9332235
OpenAlexW4287009773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.